AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 191 min read$LQDA

Saggar Rajeev sold $6.0M of LQDA

Saggar Rajeev (Chief Medical Officer) sold 79,534 shares of Liquidia Corp (LQDA) at an average of $75.09 ($74.06–$76.84, $5.97M total) across 2 trades over 2026-08-17 to 2026-08-19.

Original reporting
SEC EDGAR · Saggar Rajeev
Published Aug 19, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 10:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The insider sale provides fresh data on insider sentiment, which traders may use to adjust short-term positions.

02

Market read

New insider sale information for a small-cap biotech, modest relevance for traders tracking insider activity.

03

What to watch

No accompanying corporate news; the sale may be routine and not indicative of future performance.

Relevance 6/10Novelty 6/10Timing: filed Aug 19, 2026

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Chief Medical Officer Saggar Rajeev sold 79,534 shares for $5.97M, reducing his stake to 142,265 shares.

Expected impact

Possible modest downside pressure in the near term.

Evidence & confidence

CMO is a senior insider; a $6M sale is material for a small-cap biotech, but not large enough to trigger a major move.

Market effects

Sector

May raise concerns for biotech sector investors monitoring insider activity.

Regional

Limited to U.S. biotech investors.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be unrelated to confidence, perhaps for personal financial planning.

Key entities

  • Company
    Liquidia Corp

    Biopharmaceutical company developing drug delivery platforms.

  • Individual
    Saggar Rajeev

    Chief Medical Officer of Liquidia Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

OCT 20
$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

news.alphastreet.com1 min
OCT 16
$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

biobuzz.io7 min
OCT 15
$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.

investing.com2 min